The BRF2 antibody is a crucial tool in studying the role of BRF2 (B-related factor 2), a subunit of the transcription factor IIIB (TFIIIB) complex that regulates RNA polymerase III (Pol III)-mediated transcription. BRF2 specifically directs the synthesis of small non-coding RNAs, such as tRNAs, 5S rRNA, and other regulatory RNAs, by recruiting Pol III to target gene promoters. Unlike its paralog BRF1. BRF2 is involved in transcribing a distinct subset of Pol III-dependent genes, including certain snRNAs. Research has linked BRF2 dysregulation to oncogenesis, particularly in cancers like head and neck squamous cell carcinoma (HNSCC), where its overexpression correlates with poor prognosis and enhanced cell proliferation. Antibodies targeting BRF2 enable researchers to investigate its expression patterns, subcellular localization, and interactions via techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation. These studies help elucidate BRF2's role in cellular homeostasis, its contribution to tumor progression, and its potential as a therapeutic target. Commercial BRF2 antibodies are typically validated for specificity and sensitivity across human and model organism samples, supporting both basic and translational research in gene regulation and cancer biology.